Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -362.50K | -247.60K | -293.50K | -263.30K | -372.90K |
| Total Depreciation and Amortization | 10.10K | 10.00K | 9.80K | 9.60K | 20.70K |
| Total Amortization of Deferred Charges | 11.60K | 11.80K | 11.50K | 11.70K | -- |
| Total Other Non-Cash Items | 181.50K | 98.40K | 106.80K | -55.80K | 140.20K |
| Change in Net Operating Assets | -63.60K | -56.00K | 82.10K | 82.80K | 29.10K |
| Cash from Operations | -222.80K | -183.50K | -83.20K | -215.00K | -182.80K |
| Capital Expenditure | -- | -- | -- | -2.10K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 201.30K | 205.30K | 114.30K | 154.00K | 86.40K |
| Cash from Investing | 201.30K | 205.30K | 114.30K | 151.90K | 86.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.00K | -- | -- | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -3.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | 7.30K | -- | -- | -2.20K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.30K | 21.80K | 31.00K | -65.40K | -96.40K |